JP2021501776A5 - - Google Patents

Download PDF

Info

Publication number
JP2021501776A5
JP2021501776A5 JP2020524641A JP2020524641A JP2021501776A5 JP 2021501776 A5 JP2021501776 A5 JP 2021501776A5 JP 2020524641 A JP2020524641 A JP 2020524641A JP 2020524641 A JP2020524641 A JP 2020524641A JP 2021501776 A5 JP2021501776 A5 JP 2021501776A5
Authority
JP
Japan
Prior art keywords
antibody
months
drug
drug conjugate
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020524641A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021501776A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/058771 external-priority patent/WO2019089973A1/en
Publication of JP2021501776A publication Critical patent/JP2021501776A/ja
Publication of JP2021501776A5 publication Critical patent/JP2021501776A5/ja
Priority to JP2023179215A priority Critical patent/JP2024009998A/ja
Pending legal-status Critical Current

Links

JP2020524641A 2017-11-02 2018-11-01 抗組織因子抗体−薬物コンジュゲートおよびがんの治療におけるその使用 Pending JP2021501776A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023179215A JP2024009998A (ja) 2017-11-02 2023-10-18 抗組織因子抗体-薬物コンジュゲートおよびがんの治療におけるその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762580877P 2017-11-02 2017-11-02
US62/580,877 2017-11-02
PCT/US2018/058771 WO2019089973A1 (en) 2017-11-02 2018-11-01 Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023179215A Division JP2024009998A (ja) 2017-11-02 2023-10-18 抗組織因子抗体-薬物コンジュゲートおよびがんの治療におけるその使用

Publications (2)

Publication Number Publication Date
JP2021501776A JP2021501776A (ja) 2021-01-21
JP2021501776A5 true JP2021501776A5 (https=) 2021-12-02

Family

ID=66332366

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020524641A Pending JP2021501776A (ja) 2017-11-02 2018-11-01 抗組織因子抗体−薬物コンジュゲートおよびがんの治療におけるその使用
JP2023179215A Pending JP2024009998A (ja) 2017-11-02 2023-10-18 抗組織因子抗体-薬物コンジュゲートおよびがんの治療におけるその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023179215A Pending JP2024009998A (ja) 2017-11-02 2023-10-18 抗組織因子抗体-薬物コンジュゲートおよびがんの治療におけるその使用

Country Status (14)

Country Link
US (2) US20210177987A1 (https=)
EP (1) EP3703757A4 (https=)
JP (2) JP2021501776A (https=)
KR (2) KR20200084874A (https=)
CN (2) CN119868579A (https=)
AU (2) AU2018358120A1 (https=)
BR (1) BR112020008593A2 (https=)
CA (1) CA3080137A1 (https=)
EA (1) EA202090741A1 (https=)
IL (2) IL274122B2 (https=)
MX (1) MX2020004265A (https=)
SG (1) SG11202003713TA (https=)
UA (1) UA129645C2 (https=)
WO (1) WO2019089973A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3735271A4 (en) 2018-01-04 2022-06-15 Iconic Therapeutics, Inc. ANTI-TISSUE FACTOR ANTIBODIES, ANTIBODY DRUG CONJUGATES AND RELATED METHODS
TWI841554B (zh) 2018-03-21 2024-05-11 丹麥商珍美寶股份有限公司 以鉑為主之劑與抗組織因子抗體-藥物共軛物的組合治療癌症之方法
WO2019217455A1 (en) 2018-05-07 2019-11-14 Genmab A/S Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
AU2019321442A1 (en) * 2018-08-16 2021-02-11 Genmab A/S Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer
TWI844571B (zh) 2018-10-30 2024-06-11 丹麥商珍美寶股份有限公司 使用抗血管內皮生長因子(vegf)抗體與抗組織因子(tf)抗體-藥物共軛體之組合以治療癌症之方法
MX2021015974A (es) * 2019-07-03 2022-04-26 Iconic Therapeutics Inc Conjugados de anticuerpos y farmacos anti-factor tisular y metodos relacionados.
MX2022005222A (es) * 2019-11-07 2022-06-08 Genmab As Metodos para tratar el cancer con una combinacion de un anticuerpo anti muerte programada 1 (pd-1) y un conjugado de anticuerpo anti factor tisular-farmaco.
MX2022015375A (es) * 2020-06-29 2023-01-16 Genmab As Conjugados de farmaco-anticuerpo anti-factor de tejido y su uso en el tratamiento de cancer.
AU2022238571A1 (en) 2021-03-18 2023-09-14 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
EP4727593A1 (en) * 2023-06-15 2026-04-22 Fortvita Biologics (Singapore) Pte. Ltd. Formulation comprising antibody-drug conjugate targeting claudin18.2, method for preparing the same, and use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2615374A1 (en) * 2005-07-18 2007-01-25 Ernest Kun Kun Treatment of cancer
WO2007058935A2 (en) * 2005-11-14 2007-05-24 Bausch & Lomb Incorporated Ophthalmic composition for dry eye therapy
UA109633C2 (uk) * 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
JP6055404B2 (ja) * 2010-06-15 2016-12-27 ゲンマブ エー/エス 組織因子に対するヒト抗体薬物結合体
PL2991683T3 (pl) * 2013-05-02 2020-03-31 Glykos Finland Oy Koniugaty glikoproteiny lub glikanu z toksycznym ładunkiem
HUE055109T2 (hu) * 2015-09-11 2021-11-29 Genmab As Adagolási rendek TF elleni antitest és gyógyszer konjugátumaihoz
CN106938051B (zh) * 2016-08-22 2019-10-11 复旦大学 靶向于组织因子的抗体-药物偶联物

Similar Documents

Publication Publication Date Title
JP2021501776A5 (https=)
IL312038A (en) Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer
JP2021518394A5 (https=)
JP2021515017A5 (https=)
JP2021523158A5 (https=)
JP2021523233A5 (https=)
JP2021534165A5 (https=)
JP2017110002A5 (https=)
JP2011507932A5 (https=)
JP2018527383A5 (https=)
RU2018111205A (ru) Терапевтические комбинации, содержащие анти-folr1 иммуноконъюгаты
TW202440170A (zh) 抗folr1免疫偶聯物與抗pd-1抗體之組合
JP2015500822A5 (https=)
IL278400B2 (en) Combination of an anti pd-1 antibody and anti tissue factor (tf) antibody drug conjugate for use in the treatment of cancer
CN112218662A (zh) 抗cd37免疫缀合物给药方案
EP3896089A1 (en) Use of il-15 protein complex joint pd-l1 antibody for treating tumor diseases
TWI870592B (zh) 使用免疫檢查點抑制劑抗體治療癌症之方法和組合
JPWO2019173523A5 (https=)
JPWO2019183253A5 (https=)
JPWO2019217457A5 (https=)
JPWO2019217455A5 (https=)
CN120437318A (zh) 抗体药物偶联物和免疫检查点抑制剂的联合应用
WO2025082449A1 (zh) 抗体药物偶联物和免疫检查点抑制剂的联合应用
JPWO2020092210A5 (https=)
JPWO2020037024A5 (https=)